Previous 10 | Next 10 |
Image source: The Motley Fool. Calithera Biosciences Inc (NASDAQ: CALA) Q2 2020 Earnings Call Aug 10, 2020 , 5:00 p.m. ET Operator Continue reading
The following companies have filed for mixed shelf offerings: More news on: Calithera Biosciences, Inc., Adaptimmune Therapeutics plc, PTC Therapeutics, Inc., Healthcare stocks news, , Read more ...
Calithera Biosciences, Inc. (CALA) Q2 2020 Earnings Conference Call Aug 10, 2020, 05:00 PM ET Company Participants Jennifer McNealey - IR Susan Molineaux - Founder, President and CEO Keith Orford - Chief Medical Officer Stephanie Wong - SVP of Finance Conference Call Partici...
Calithera Biosciences (NASDAQ: CALA ) : Q2 GAAP EPS of -$0.29 beats by $0.05 . More news on: Calithera Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
--Calithera to Provide Corporate Update via Conference Call and Webcast at 2:00 p.m. PT on August 10, 2020-- SOUTH SAN FRANCISCO, Calif., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and develop...
SOUTH SAN FRANCISCO, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today anno...
SOUTH SAN FRANCISCO, Calif., July 14, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences announced today the appointment of Scott Garland to its board of directors. Garland is a 29-year veteran of the biopharmaceutical industry who most recently served as the president and chief executive offic...
Calithera Biosciences (NASDAQ: CALA ) has dosed the first patients in its Phase 1b clinical trial of the arginase inhibitor CB-280 in adult patients with cystic fibrosis (CF) and chronic airway infection. More news on: Calithera Biosciences, Inc., Healthcare stocks news, Read more .....
SOUTH SAN FRANCISCO, July 13, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that it...
KEAPSAKE is a planned Phase 2 randomized trial exploring telaglenastat with standard of care in first-line treatment of patients with lung cancer with KEAP1/NRF2 mutations SOUTH SAN FRANCISCO, Calif., May 29, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinic...
News, Short Squeeze, Breakout and More Instantly...
Calithera Biosciences Inc. Company Name:
CALA Stock Symbol:
OTCMKTS Market:
Calithera Biosciences Inc. Website:
Williams Industrial Services Group Inc. (WLMSQ) is expected to report $-0.15 for Q3 2023 Cellcom Israel Limited (CELJF) is expected to report for quarter end 2023-09-30 Central Japan Railway Co ADR (CJPRY) is expected to report for Q2 2024 CW Petroleum Corp (CWPE) is expected to repor...
Strategic Environmental & Energy Resources Inc (SENR) is expected to report for Q1 2024 Biocept Inc. (BIOCQ) is expected to report for Q1 2024 Kalera Public Limited Company (KALRQ) is expected to report for quarter end 2023-09-30 Lanvin Group Holdings Limited (LANV) is expected to...
Murata Manufacturing Co. Ltd. ADR (MRAAY) is expected to report $0.27 for Q2 2024 Quotient Limited (QTNTQ) is expected to report for quarter end 2023-09-30 Evaxion Biotech A/S (EVAX) is expected to report for Q3 2023 American Virtual Cloud Technologies Inc. (AVCTQ) is expected to repo...